Therapeutic Drug Monitoring of Elexacaftor, Tezacaftor, and Ivacaftor: An Overview of Bioanalytical Methods
Although CFTR modulators meet many of the established criteria for therapeutic drug monitoring, critical gaps persist, particularly regarding exposure-response relationships and optimal sampling strategies. Addressing these issues will be essential to establish therapeutic drug monitoring as a reliable tool for personalizing CFTR modulator therapy in patients with cystic fibrosis.
Authors
- Alessia Cafaro (ORCID: https://orcid.org/0000-0003-1132-1267)
- Giuliana Cangemi (ORCID: https://orcid.org/0000-0001-6847-5983)
- Sebastiano Barco (ORCID: https://orcid.org/0000-0002-1148-427X)
- Carlo Castellani (ORCID: https://orcid.org/0000-0003-1916-0963)
Institutions
- Istituto Giannina Gaslini (IT)
Publication Details
- Journal
- Therapeutic Drug Monitoring
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1097/ftd.0000000000001408
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00